 |
|
Nonstroke Treatment—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
Hippocrates urged us, first, do no harm, but this should not be overinterpreted to accept no risks in making treatment decisions. Such a stance would leave us paralyzed as physicians because nearly every medical therapy and surgical intervention has a risk of complications. It is the calculus of the risk-benefit ratio that must be considered in making treatment decisions, and there has been a common misunderstanding of the math relevant to using tPA for stroke.
Dr Landau echoes articles from the period when the initial results from the National Institute of Neurological Disorders and Stroke (NINDS) trial1 first appeared before all information from the various trials was fully analyzed.2-4 These misconceptions of, and this resistance to, tPA therapy remain despite a decade of published scholarly literature supporting a more favorable view of the treatment.5
Intracerebral hemorrhage rates increase when tPA is administered, and many affected patients do poorly. . . . [Full Text of this Article] AUTHOR INFORMATION
Kara Z. Bambauer, PhD;
S. Claiborne Johnston, MD;
Derek E. Bambauer, JD;
Justin A. Zivin, MD, PhD
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Nonstroke Treatment
William M. Landau
Arch Neurol. 2006;63(10):1506.
EXTRACT
| FULL TEXT
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Kara Z. Bambauer, S. Claiborne Johnston, Derek E. Bambauer, and Justin A. Zivin
Arch Neurol. 2006;63(5):661-664.
ABSTRACT
| FULL TEXT
|
